Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 10 for:    "Thalassemia" | "Calcium"

B-Thalasaemia Trait and Its Possible Cardioprotective Role

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02428023
Recruitment Status : Unknown
Verified January 2016 by ANDREANIDIS ELIAS, 404 General Military Hospital, Larissa.
Recruitment status was:  Recruiting
First Posted : April 28, 2015
Last Update Posted : January 11, 2016
Sponsor:
Information provided by (Responsible Party):
ANDREANIDIS ELIAS, 404 General Military Hospital, Larissa

Brief Summary:
Our purpose is to investigate whether thallasaemia trait offers protection against cardiovascular events and whether this can be applied to specific characteristics of these people ( better lipid profile , better blood pressure profile) as scientific literature suggests.

Condition or disease
Beta-Thalassemia Trait Coronary Artery Disease

Detailed Description:
Thallasaemia is a major problem , especially in countries around the Mediterranean sea.On the other hand ,thallasaemia trait has been shown ,in a small number of studies , to have a possible protective role against CAD and stroke.These kind of studies have been contacted in Greece also ,and usually they enroll a small number of participants. In the study, investigators will enroll 2500 subjects who serve in military units in Thesally Greece. Firstly investigators will estimate the prevalence of thallasaemia trait in this population , as it is very high in this region and at the same time investigators will retrospectively record data from their personal files (which are annually recorded).

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2500 participants
Observational Model: Case Control
Time Perspective: Cross-Sectional
Target Follow-Up Duration: 5 Years
Official Title: B-Thalasaemia Trait and Its Possible Cardioprotective Role
Study Start Date : March 2015
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : April 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Thalassemia

Group/Cohort
GrThalasaemia
estimation of IMT of the carotides arteries and calcium scoring
GrNormal
estimation of IMT of the carotides arteries and calcium scoring



Primary Outcome Measures :
  1. Cardioprotective role of Thalassemia Treat [ Time Frame: 1 YEAR ]
    Cardioprotective role of Thalassemia Treat



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 57 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
2500 subjects who serve in military units in Thessaly Greece
Criteria

Inclusion Criteria:

  1. voluntary participation,
  2. Subjects with Thalassemia treat will be confirmed of their treat by electrophoresis -

Exclusion Criteria:

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02428023


Contacts
Layout table for location contacts
Contact: Elias Andreanidis, PhD +3 6944570406 elandreanides@gmail.com
Contact: Maria Malliarou, PhD +3 6944796499 mmalliarou@gmail.com

Locations
Layout table for location information
Greece
404 Military Hospital Recruiting
Larissa, Greece
Contact: ELIAS ANDREANIDES, PhD    +3 6944570406    elandreanides@gmail.com   
Contact: Maria Malliarou, PhD       mmalliarou@gmail.com   
Sponsors and Collaborators
404 General Military Hospital, Larissa
Investigators
Layout table for investigator information
Principal Investigator: Elias Andreanidis, PhD 404 General Military Hospital, Larissa

Additional Information:

Layout table for additonal information
Responsible Party: ANDREANIDIS ELIAS, Director of Cardiology Department, 404 General Military Hospital, Larissa
ClinicalTrials.gov Identifier: NCT02428023     History of Changes
Other Study ID Numbers: 404 General Military Hospital
First Posted: April 28, 2015    Key Record Dates
Last Update Posted: January 11, 2016
Last Verified: January 2016
Keywords provided by ANDREANIDIS ELIAS, 404 General Military Hospital, Larissa:
Thalassemia
trait
coronary
stroke
Additional relevant MeSH terms:
Layout table for MeSH terms
Thalassemia
beta-Thalassemia
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn